WORTH THE AIRFARE –
Sept. 21, 2022 – In recent decades, after a strong renaissance of clinical research around ibogaine and other mind-expanding drugs, psychedelic-assisted therapies are becoming increasingly popular as viable alternatives for patients who do not respond to conventional treatments. Ibogaine is an hallucinogen originally produced by the iboga shrub of West Africa and its application is being researched in the treatment of addiction to opiates and other substances. Ketamine, for its part, is a synthetic dissociative drug producing psychedelic-like effects. Originally approved as an anesthetic, ketamine is currently used to quickly recover patients from acute states of extreme depression or suicidal ideation.
The use of both substances to treat different mental health conditions is authorized in Brazil, as long as it is performed under proper medical supervision and in a hospital setting.
